Aerocrine AB (STO:AERO-B) announces that the result of a clinical
conducted by a group of highly recognized experts was published today in
the medical journal Respiratory Medicine. The article outlines a guide
for how to interpret the value of Fractional exhaled Nitric Oxide (FeNO)
in suspected asthma patients and in the management of asthma patients on
What´s new from previously published FeNO guidelines2 is that for
patients with values in the "grey zone", between 25 to 50 ppb the
authors now give clear treatment recommendations, based on newest
clinical documentation. With this approach, measurement of airway
inflammation becomes central in assisting with an accurate initial
diagnosis of asthma and in the ongoing therapy monitoring and management
to achieve the most successful outcomes.
An important attribute of FeNO is its ability to potentially predict if
a patient will respond to ICS therapy, thus avoiding the need to put
patients on ICS therapy unnecessarily with a "see-if-it-works" approach.
This new view on how to interpret the FeNO value will help general
practitioners and other asthma treating physicians to optimize
therapeutic control - step up and step down of inhaled corticosteroid,
according to the amount of airway inflammation present. Several recent
publications have shown FeNO-guided management to result in improved
asthma symptom control and up to 50% reduction in exacerbation
frequency, compared with standard physician based management which is
carried out today. 3,4,5 (Syk, Peirsman, Powell)
Moreover FeNO-guided management of patients allows physicians to monitor
patient adherence to anti-inflammatory therapy and to predict risk of
future exacerbations6 or decline in lung function7.
"After looking at all the existing clinical data we can conclude that
FeNO is a direct biomarker of Th2 driven airway inflammation such as
asthma. The FeNO value when interpreted in clinical context is an
important decision aid for the practising physician, and should be used
more often in both secondary and primary care." says Leif Bjermer,
Professor of Allergy and Respiratory Medicine at Lund University in
Sweden and one of the authors.
"The conclusions made by this group of 11 distingished and
well-respected experts across 7 countries is in line with the newly
announced health technology assessment made by the UK National Institute
for Health and Care Excellence (NICE), in which NICE recommends FeNO*
testing for many aspects of asthma care. These are important steps for
Aerocrine as we continue to establish FeNO as a global standard of care
for inflammatory airway diseases," says David Plotts, VP International
Sales & UK General Manager Aerocrine.
The FeNO test and its developers, Aerocrine AB, emerged from the 1998
Nobel Prize in medicine. Aerocrine offers versatile and easy-to-use
monitoring devices for FeNO-testing. Aerocrine's compact hand-held
devices for clinical applications are used for routine measurements in
both specialist and primary care clinics and can be used to improve the
management of allergic airway inflammation, such as asthma.
NIOX VERO® and NIOX MINO® offer added advantages for patient care,
including detecting allergic airway inflammation, determining the
likelihood of corticosteroid responsiveness, monitoring of airway
inflammation to determine the potential need for corticosteroid, and
unmasking of otherwise unsuspected non-adherence to corticosteroid
therapy. FeNO-testing can also be of help in finding the optimum
corticosteroid dosing, which is important to promote patient safety,
whilst maintaining adequate control and minimising exacerbations.
The said review, published in the printed edition of Respiratory
Medicine, was supported by a grant from Aerocrine.
1. Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G,
Price D, Roche N, Sastre J, Thomas M, Usmani O, Current evidence and
future research needs for FeNO measurement in respiratory diseases,
Respiratory Medicine (2014), doi: 10.1016/j.rmed.2014.02.005.
2. Dweik RA, Boggs PB, Erzurum SC, et al; An official ATS clinical
practice guideline: interpretation of exhaled nitric oxide levels (FeNO)
for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615.
3. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in
pregnancy guided by measurement of fraction of exhaled nitric oxide: a
double-blind, randomised controlled trial. Lancet.
4. Peirsman E, Carvelli T, Hage P, Hanssens L, Pattyn L, Raes M,
Sauer K, Vermeulen F, Desager K. Exhaled Nitric Oxide in childhood
allergic asthma management a randomised controlled trial. Pediatric
5. Syk A, Malinovschi A, Johansson G, Unden A, Andreasson A, Lekander M,
Alving K. Anti-inflammatory Treatment of
Atopic Asthma Guided by Exhaled Nitric Oxide: A Randomized, Controlled
Trial. J Allergy Clin Immunol 2013. 4
6. Gelb AF, Taylor CF, Shinar CM, Gutierrez C, Zamel N. Role of
spirometry and exhaled nitric oxide to predict exacerbations in treated
asthmatics. Chest 2006;129:1492-9.
7. van Veen I, ten Brinke A, Sterk P, Sont J, Gauw S, Rabe K and Bel E,
Exhaled nitric oxide predicts lung function decline in
difficult-to-treat asthma Eur Respir J 2008; 32: 344-349
Aerocrine AB is a medical technology company focused on the improved
management and care of patients with inflammatory airway diseases. As
the pioneer and leader in technology to monitor and manage airway
inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both
products enable fast and reliable management of airway inflammation and
may therefore play a critical role in more effective diagnosis,
treatment and follow-up of patients with inflammatory airway diseases
such as asthma. Aerocrine is based in Sweden with subsidiaries in the
U.S., Germany and the U.K. Aerocrine shares were listed on the Stockholm
Stock Exchange in 2007. For more information please visit www.aerocrine.com
This information was brought to you by Cision http://news.cision.com
[ Back To NFVZone's Homepage ]